Characterization of treatment resistance and viral kinetics in the setting of single- versus dual-active monoclonal antibodies against SARS-CoV-2.

Manish C ChoudharyRinki DeoTeresa H EveringKara W ChewMark J Giganti Carlee B MoserJustin RitzJames ReganJames P FlynnCharles R CrainDavid Alain WohlJudith S CurrierJoseph J EronDavid MargolisQing ZhuLijie ZhonLi YaAlexander L GreningerMichael D HughesDavey SmithEric S DaarJonathan Z Linull null

Published in: The Journal of infectious diseases (2024)

Compared to single-active mAb therapy, dual-active mAbs led to similar clinical outcomes, but significantly faster viral load decline and a lower risk of emergent resistance.

Keyphrases

sars cov
respiratory syndrome coronavirus
stem cells
combination therapy
bone marrow
monoclonal antibody
replacement therapy